The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 27, 2020

Filed:

Jun. 10, 2015
Applicant:

Molecular Templates, Inc., Austin, TX (US);

Inventors:

Eric Poma, New York, NY (US);

Erin Willert, Round Rock, TX (US);

Jack Higgins, Georgetown, TX (US);

Jason Kim, Austin, TX (US);

Assignee:

Molecular Templates, Inc., Austin, TX (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/24 (2006.01); C07K 14/245 (2006.01); C07K 14/25 (2006.01); C07K 14/74 (2006.01); C07K 14/705 (2006.01); C07K 16/08 (2006.01); C07K 16/10 (2006.01); C07K 16/20 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C12N 9/10 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/2497 (2013.01); C07K 14/245 (2013.01); C07K 14/25 (2013.01); C07K 14/70539 (2013.01); C07K 14/70596 (2013.01); C07K 16/085 (2013.01); C07K 16/088 (2013.01); C07K 16/1063 (2013.01); C07K 16/18 (2013.01); C07K 16/20 (2013.01); C07K 16/286 (2013.01); C07K 16/2866 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12N 9/1077 (2013.01); C12Y 204/02036 (2013.01); C12Y 302/02022 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/33 (2013.01); C07K 2319/55 (2013.01); C07K 2319/74 (2013.01);
Abstract

The present invention provides protease-cleavage resistant molecules comprising Shiga toxin effector polypeptides capable of exhibiting potent, Shiga toxin functions (e.g. subcellular routing and cytotoxicity). The present invention also provides protease-cleavage resistant, cell-targeting molecules for targeting specific cell types, e.g., infected or malignant cells. Certain molecules of the present invention are cytotoxic, and certain cell-targeting molecules of the present invention may be used for the targeted killing of specific cell types and the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections. Certain cell-targeting molecules of the invention exhibit improved, in vivo tolerability as compared to related cell-targeted molecules comprising protease-cleavage sensitive, wild-type, Shiga toxin effector polypeptides. The cell-targeting molecules of the invention can deliver additional materials, such as, e.g., antigens, cytotoxic agents, and detection-promoting agents, into the interiors of target cells.


Find Patent Forward Citations

Loading…